Table 3. Kaplan–Meier survival estimates of disease-specific survival (DSS) and associated hazard ratios for individual HPV diagnostic tests.
| DSS | Three-year survival probability | 95% CI | Log-rank P-value | Hazard ratio | 95% CI | P-value |
|---|---|---|---|---|---|---|
|
HR-HPV RNAscope | ||||||
| HPV −ve | 0.6 | 0.45–0.8 | 0.0011 | 11.9 | 1.6–90.8 | 0.017 |
| HPV +ve |
0.96 |
0.88–1.0 |
|
|
|
|
|
HR-HPV qRT–PCR | ||||||
| HPV −ve | 0.62 | 0.47–0.81 | 0.0026 | 10.2 | 1.2–77.9 | 0.025 |
| HPV +ve |
0.95 |
0.87–1.0 |
|
|
|
|
|
p16 IHC | ||||||
| HPV −ve | 0.61 | 0.46–0.82 | 0.0093 | 4.1 | 1.1–14.6 | 0.031 |
| HPV +ve |
0.9 |
0.81–1.0 |
|
|
|
|
|
HR HPV DNA ISH | ||||||
| HPV −ve | 0.63 | 0.48–0.82 | 0.0074 | 5.2 | 1.2–23.3 | 0.031 |
| HPV +ve |
0.92 |
0.82–1.0 |
|
|
|
|
|
p16 IHC/HR-HPV DNA ISH | ||||||
| HPV −ve | 0.63 | 0.48–0.82 | 0.0074 | 5.2 | 1.2–23.3 | 0.031 |
| HPV +ve |
0.92 |
0.82–1.0 |
|
|
|
|
|
DNA qPCR | ||||||
| HPV −ve | 0.62 | 0.47–0.82 | 0.0035 | 5.5 | 1.2–24.6 | 0.025 |
| HPV +ve |
0.92 |
0.82–1.0 |
|
|
|
|
|
p16 IHC/DNA qPCR | ||||||
| HPV −ve | 0.62 | 0.47–0.81 | 0.0022 | 10.6 | 1.4–80.8 | 0.023 |
| HPV +ve | 0.95 | 0.87–1.0 | ||||
Abbreviations: CI=confidence interval; HR-HPV=high-risk human papillomavirus; IHC=immunohistochemistry; ISH=in situ hybridisation; qPCR=quantitative PCR; qRT–PCR=quantitative reverse transcriptase PCR.